Introduction
Human papillomavirus types are found predominantly in cervical carcinomas (Boshart et al., 1984; Dfirst et al., 1983; Fuchs et al., 1988; McCance et al., 1985; Schneider et al., 1985) . HPV-6 and HPV-11, on the contrary, are found predominantly in benign condylomata or laryngeal papillomas (Gissmann et al., 1982 (Gissmann et al., , 1983 . The oncogenic potential of HPV-16 and HPV-18 has been amply documented in vitro (Matlashewski et al., 1987; Pater et al., 1988; Storey et al., 1988) . In vitro analysis of HPV-6 and HPV-11 indicates that they do not share with HPV-16 and HPV-18 an oncogenic potential that can be readily demonstrated (Pater et al., 1988; Storey et al., 1988) but, on occasion, HPV-6 or HPV-11 is found in a malignant lesion (Byrne et al., 1987; Diirst et al., 1983; Gissmann et al., 1982 Gissmann et al., , 1983 Manias et al., 1989; Rando et al., 1986a; Sutton et al., 1987; Wu & Mounts, 1989) . We have cloned an HPV-6 from a poorly differentiated, t Present address: Virology Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285-0438, U.S.A.
non-keratinizing squamous cell carcinoma of the vulva (Kasher & Roman, 1988a) to determine whether HPV-6 from a malignant lesion has an oncogenic potential similar to that of HPV-16 and HPV-18, which would explain its association with the malignancy. Alternatively, its oncogenic potential could be low, similar to HPV-6 from a benign lesion. In this case, other explanations for its role in the genesis of the tumour would have to be proposed. Experiments were designed to distinguish between these two alternatives.
The HPV genome is organized into open reading frames (ORFs) which encode early and late viral proteins and an upstream regulatory region (URR) which contains promoters, enhancers and possibly the origin of DNA replication. The products of the HPV-16 and HPV-18 E6 and E70RFs are required for efficient immortalization and restricted differentiation of primary human keratinocytes (Barbosa & Schlegel, 1989; Hawley-Nelson et al., 1989 , Hudson et al., 1990 Kaur & McDougall, 1989; Munger et al., 1989) and the product of the E70RF can cooperate with an activated ras gene to transform baby rat kidney (BRK) cells (Matlashewski et al., 1987; Pater et al., 1988; Storey et al., 1988) . The E7 ORFs of HPV-6 and HPV-l 1 are able to cooperate with ras with a much lower efficiency than the E70RFs of HPV-16 and HPV-18 and are able to do so only when expressed from a heterologous promoter (Storey et al., 1990) . The difference in the oncogenic potential of an HPV-6 present in a malignant versus a benign lesion could therefore be due to differences in the sequences of the E6 and E70RFs or differences in enhancer strength which could lead to increased expression of E6 and E7 proteins.
The prototype HPV-6b genome, cloned from a condyloma (Schwarz et al., 1983) , has been shown to contain a 120 bp deletion in the URR due to a cloning artefact (Boshart & zur Hausen, 1986 ). In addition, we have previously shown that the 5' end of the HPV-6b URR can become altered during amplification in Escherichia coli (Kasher & Roman, 1988 b) . We therefore cloned an HPV-6 genome from a vulvar condyloma, HPV6-W50, to compare with the HPV-6 genome cloned from the vulvar carcinoma, HPV6-T70.
Here we describe the direct comparison of HPV6-W50 to HPV6-T70 with respect to DNA sequence and two functional assays. The sequences of the URRs of the two genomes varied from the prototype HPV-6b as well as from each other; however, no sequence differences that alter the E6 and E7 proteins were found. In a transient expression assay, comparable enhancer activity was seen with the URR of HPV6-T70 and HPV6-W50. A comparison of the ability of the two HPV-6 genomes to cooperate with an activated ras gene to transform BRK cells indicated that HPV6-T70 did not have an increased oncogenic potential. The results of these two functional assays suggest that the difference in the original lesions from which the two genomes were cloned was due to changes in the cellular environment rather than differences in the oncogenic potential of the two viral genomes.
Methods
Cloning of HPV-6 DNA from a condyloma. The cloning of HPV6-W50 and restriction enzyme analysis were as previously described for HPV6-T70 (Kasher & Roman, 1988a) . Briefly, total cellular DNA isolated from a vulvar condyloma, designated wart 50 (W50), was digested with EcoRI and size-fractionated by sucrose gradient centrifugation. DNA of approximately 8 kb was cloned into bacteriophage 2 gtWES-lambda B. HPV-6-positive plaques were identified, the recombinant phage was amplified in E. coli and the" DNA was purified. The HPV6-W50 DNA was then subcloned into the EcoRI site of pML2d to generate pHPV6-W50. All cloned DNA was propagated in E. coli strain BE257/recA (Rao & Rogers, 1978) .
AmPlification and sequencing of W50 and 170 DNA. HPV-6 URR sequences present in total cellular DNA isolated from W50 and T70, the vulvar carcinoma from which pHPV6-T70 was cloned (Kasher & Roman, 1988a) , were amplified and sequenced according to the following protocol. The polymerase chain reaction (PCR) was carried out as recommended by the manufacturer (Cetus). Dideoxynucleotide sequencing of the cloned and PCR-amplified DNA was done with a Sequenase kit (US Biochemicals) following the manufacturer's instructions. All numbering refers to the sequence of the prototype HPV-6b (Schwarz et al., 1983) . The oligonucleotide primers used to amplify the URR sequences were from nucleotides (nt) 7229 to 7252 on the coding strand and 7490 to 7468 on the non-coding strand. The sequence of the PCR products was determined using end-labelled primers containing nt 7259 to 7276 and 7450 to 7434. Sequencing of the cloned URR was done using primers containing nt 7229 to 7252, 7515 to 7529 and 7752 to 7766 on the coding strand, and 7450 to 7434 and 93 to 71 on the non-coding strand. The cloned E60RF was sequenced with primers containing nt 7868 to 7883 and 592 to 577 from the coding and non-coding strand, respectively; the cloned E70RF was sequenced with primers containing nt 418 to 432 and 836 to 822 from the coding and non-coding strand, respectively.
Plasmids containing the URR of HP V6-W50 and HP V6-T70. Plasmids pW50a, pW50b, pT70a and pT70b were constructed by digesting pHPV6-T70 and pHPV6-W50 with Ndel, gel purifying the fragments corresponding to nt 6498 to 235 (1733 bp for W50 and 1670 bp for T70), digesting with DpnI (nt 7151) and gel purifying the NdeI-DpnI fragments (1080 bp for W50 and 1017 bp for T70). NdeI linkers were added and the fragment was cloned into the NdeI site of pSVEcat upstream of the simian virus 40 (SV40) early promoter and the chloramphenicol acetyltransferase (CAT) gene . To verify that the cloned URRs contained authentic HPV sequences, each new plasmid preparation was sequenced.
Cells and transfections to analyse enhancer activity. HeLa cells (obtained from Dr L. Laimins, University of Chicago, Ill., U.S.A.) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% newborn calf serum and 100 ~tM-gentamicin. Vero cells were grown in DMEM supplemented with 10% heatinactivated calf serum and 100 ixM-gentamicin. Cells were seeded at 106 per 10 cm dish the day before transfection and the medium was changed 2 h prior to transfection. Transfections were done by the calcium phosphate coprecipitation method (Graham & van der Eb, 1973) using 10 ~tg test DNA, 2-5 I~g pRSVflgal DNA (Thierry & Yaniv, 1987) and 7.5 ~tg sonicated salmon sperm DNA. The cells were incubated for 4 to 6 h at 37 °C and then shocked with 15% glycerol in 1 x HBS (25 mM-HEPES, 140 mM-NaCI, 0-75 mM-Na2HPO 4 pH 7.1) for 90 s at room temperature. The cells were rinsed with 1 x TD (25 mM-Tris, 135 mM-NaCI, 5 m~-KCI, 0.7 mM-Na2HPO4 pH 7.4), fresh medium was added and the incubation was continued at 37 °C for 48 h.
CAT and fl-galactosidase assays. Cells were harvested at 48 h posttransfection and cell extracts were made by freezing and thawing (Gorman et al., 1982) . The protein content of the cell extracts was determined by the Bio-Rad protein assay. To remove potential inhibitory factors, 1 lal 0-5 M-EDTA was added to the extracts which were then heated to 65 °C for 10 min and centrifuged for 5 min to remove debris (Crabb et al., 1989) . The CAT assay (Gorman et al., 1985) was modified as follows. Protein (2.5 to 25 ~tg) was diluted to 100 ~tl with 0.25 M-Tris-HCI pH 7.8, to which was added 0.025 ~tCi [14C]chloramphenicol, 1.5 ~tl water and 2.5 Ixl 40 mM-acetyl-CoA, and incubated at 37 °C for 1 h. The [14C]chloramphenicol was extracted with 1 ml ethyl acetate and separated by thin-layer chromatography. Thin-layer chromatography plates were scanned using an AMBIS beta scanner and the percentage conversion to acetylated chloramphenicol was determined. To determine fl-galactosidase ~-gal) activity, 20 p.l unheated extract was added to 380 ~tl Z buffer (100 mr, t-sodium phosphate buffer, 10 mM-KCI, 1 mM-Mg2SO4, 50 mM-2-mercaptoethanol) and 80 Ixl o-nitrophenyl fl-D-galactoside (4 mg/ml in 100 mMsodium phosphate buffer pH 7-0) and incubated at 37 °C (Miller, 1972) . Relative fl-gal activity was determined by measuring A42 o. To correct for differences in transfection efficiency, the CAT activity was normalized with the corresponding ~-gal activity for each transfection.
Transformation of baby rat kidney cells. BRK cell cultures were initiated from 3 or 8 day old Fisher rats. The medium was changed 8 to 10 h after plating. After an additional 4 h, the cells were transfected with 15 Ixg pHPV DNA (pHPV18; pHPV6-W50.1, a single copy of HPV6-W50 inserted into pML2d at the unique BamHI site; or pHPV6-T70.2, two head-to-tail copies of HPV6-T70 inserted into pML2d at the unique EcoRI site), 10 ~tg pEJras DNA (Shih & Weinberg, 1982) and 5 ktg pSV2neo DNA (Southern & Berg, 1982) per 6 cm dish using the modification of the calcium phosphate coprecipitation method described by Wigler et al. (1979) : BBS (25 mM-BES pH 6.95, 140 mMNaC1, 0.75 mM-Na2HPO4) rather than HBS was used in the transfection (Chen & Okayama, 1987) . After overnight incubation, the cells were exposed to 15~ glycerol in 1 x HBS for 60 s at room temperature, fresh medium was added and the cells were incubated overnight. Cells from one 6 cm dish were then transferred to a 10 cm dish and incubated in DMEM supplemented with 10~ foetal calf serum, 200 ~tg/ml Geneticin (G418) and 10 -6 M-dexamethasone. Foci, colonies of morphologically transformed cells, were scored at 3 weeks. 
Cloning and restriction analysis of HPV6-W50 and HP V6-T70
Total cellular DNA was extracted from a vulvar condyloma (W50) and subjected to Southern blot analysis using HPV-6b as a probe. Uncut DNA showed three bands at the predicted positions for forms I, II and III DNA, suggesting that the HPV genome was present as an episome (Fig. 1 ). This was confirmed by digestion with BclI, a no-cut enzyme for HPV-6b (data not shown), and DpnI, a no-cut enzyme for DNA replicated in mammalian cells, which yielded bands identical to those of the uncut DNA (Fig. 1) (Kasher & Roman, 1988a) (Fig. 2) . Differences in the Avail restriction fragments of the two cloned DNAs were found to reside in the URR. Other restriction site variability did not result in detectable fragment size differences. The region of the URR in which the size difference was detected was amplified from total cellular DNA isolated from the tissue specimens. Primers that flanked Ps, PstI ; H, HpaI ; P, PpuMl ; F, FnuDII ; E, EcoRI ; N, NdeI. the AvalI site were used to determine whether the size difference was authentic or the result of a cloning artefact. The resulting PCR products were separated on a 2~ agarose gel. The estimated size of the HPV6-W50 product was 355 bp, which is 95 bp greater than that predicted from the prototype HPV-6b sequence. The size of the HPV6-T70 product was 295 bp, approximately 35 bp larger than the prototype (Kasher & Roman, 1988a) (Fig. 3) . (Auborn et al., 1989) , CCNGTNAC and CAATAAACAAT; AP1 (Angel et al., 1987) and AP3 , TGAGTCAG and ACTTTCCACA; GRE (Jantzen et al., 1987) , GGTACANN-NYGTTCT; cytokeratin (Blessing et aL, 1987) , TTTGGCTT; SPHI (Davidson et al., 1988) , AAGCATGCA; NFI and NFIII (Pruijn et al., 1986) , AGCCAA and TATGATAATGAG; E2-responsive element (Spalholz et al., 1987) , ACCNoGGT.
Sequencing of PCR-generated and cloned DNA
The sequences of HPV6-W50 and HPV6-T70 were compared to that of the prototype HPV-6b (Fig. 4) . The numbering system for all comparisons and positions of insertions and deletions is that of the HPV-6b genome (Schwarz et al., 1983) . Sequencing of the cloned HPV6-T70 DNA had revealed that the increased size of the Avail restriction fragment was due to a 24 bp insertion at nt 7323, a 58 bp insertion at nt 7350, and a 49 bp deletion ofnt 7351 to 7399 (Kasher & Roman, 1988a) . The cloned HPV6-W50 DNA was sequenced to determine the identity of the extra nucleotides in the AvalI restriction fragment and a 94 bp insertion was found at nt 7350. The first 58 bp were identical to those of the insertion in HPV6-T70 with the exception of one base change. To verify the authenticity of these changes in the sequences of the cloned DNA, PCR-amplified DNA (Fig. 3) was sequenced. Sequencing of the PCR-amplified DNA confirmed that the insertions and deletions of the cloned DNA were present in the DNA extracted from the tissues. Further sequencing of HPV6-T70 did not show any other sequence changes within the URR (nt 7292 to 101) in comparison with HPV-6b. Single base pair changes were detected in the HPV6-W50 clone at nt 7373 (G to T), 7585 (A to C), 7654 (C to A), 7860 (G to A) and 27 to 28 (two bp deletion). The sequences of HPV6-W50 and HPV6-T70 were examined for homologies to known nuclear proteinbinding motifs using a DNA sequence comparison program, SEQFN, and the locations of possible nuclear factor binding sites and binding sites for the HPV E2 protein were identified (Fig. 4) . With the exception of the CEBP binding sites, the number and location of the putative binding sites were unchanged by the insertions and deletions in the URRs.
The E6 and E7 ORFs of HPV6-W50 and HPV6-T70 were also sequenced to determine any differences between the two genomes. No differences existed between the HPV6-T70 DNA and HPV-6b in either of the two ORFs. Sequencing of the E6 and E 7 0 R F s of HPV6-W50 revealed two base pair changes. A change at nt 221 (A to T) did not alter the coding sequence of the E6 ORF but did create an extra PstI site, confirming the results of the restriction enzyme analysis (Fig. 2) . A second change at nt 473 (G to A) destroyed the FnuDII site at nt 472 but left the E 6 0 R F coding sequence intact (Fig. 2) .
Determination of enhancer activity
The presence of sequence differences in the URR prompted us to compare the enhancer activities of HPV6-W50 and HPV6-T70. The URRs of HPV6-W50 and HPV6-T70 were cloned upstream of the SV40 early promoter in the enhancerless CAT expression vector, pSVEcat, pW50a and pW50b contain the entire URR of HPV6-W50 in the sense and antisense orientations, respectively; similarly, pT70a and pT70b contain the entire URR of HPV6-T70 cloned in the sense and antisense orientations, respectively. These plasmids were each cotransfected with pRSVflgal, encoding fl-gal, into the permanent cell lines HeLa and Vero and the CAT activity was determined. The CAT activity from cells transfected with each of the plasmids was compared to that of the negative control, pSVEcat; the pIasmid pSV2cat (Gorman et al., 1982) , containing the SV40 enhancer, was included as a positive control. The CAT activity was reported both before and after normalization for fl-gal activity (Fig. 5) , which was used to correct for differences in transfection efficiencies. The results were then normalized to pSVEcat activity. The average normalized enhancer activity of several transfections in HeLa and Vero cells was determined (Table 1 ). The transfections in each of the cell lines were conducted with three different plasmid preparations of pW50a, pW50b, pT70a and pT70b. In the HeLa cells, comparable enhancer activity was seen with HPV6-W50 and HPV6-T70 ( Fig. 5 ; Table 1 ). The amount of CAT activity varied between 5.0-and 11.3-fold greater than that of the enhancerless plasmid pSVEcat, regardless of orientation. In the Vero cell line, little or no enhancer activity was seen. The amount of normalized CAT activity was 0.7-to 1.4-fold that of the pSVEcat activity (Table 1) .
Analysis of the ability of HPV6-T70 and HPV6-W50 to cooperate with an activated ras gene in the transformation of BRK cultures
The HPV-16 and HPV-18 genomes can cooperate with an activated ras gene to transform BRK cells (Matlashewski et al., 1987; Pater et al., 1988; Storey et al., 1988) . Under similar conditions neither the HPV-6 nor HPV-11 genomes can transform BRK cells (Pater et al., 1988; Storey et al., 1988) . To determine whether the oncogenic potential of HPV6-T70 was greater than that of HPV6-W50, we cotransfected BRK cells with each HPV genome under the control of its own URR and an activated ras gene. HPV-18 was included as a positive control and pML2d was a negative control; we assumed that HPV6-W50 would also be a negative control. Analysis of HPV6-W50 was necessary since previously reported experiments (Storey et al., 1988) had been conducted with HPV-6b which contains a cloning artefact in the URR (Boshart & zur Hausen, 1986) . The results of three experiments using BRK cultures initiated from 8 day old rats indicated that HPV6-T70 had no * Number of foci is the number of morphologically transformed colonies per experiment.
greater ability than HPV6-W50 to cooperate with an activated ras gene; indeed, the level of activity was no greater than that of ras alone (Table 2 ). In contrast, the positive control, HPV-18, did give rise to a significantly greater number of foci (Table 2) . Similar results were obtained using BRK cultures initiated from 3 day old rats (data not shown).
Discussion
The fact that HPV-6 is only rarely associated with malignancies but commonly associated with benign warts could have two explanations. Firstly, on rare occasions a mutation may occur in the HPV-6 genome which converts it to an oncogenic form, similar in properties to HPV-16 and HPV-18. Such mutations could be either in regulatory regions affecting the level of gene expression or in coding regions. Secondly, the HPV-6 in the malignancy may be similar to that in the benign lesion and it is rarely associated with malignancy because the malignancy arises following the rare accumulation of cellular mutations causing the loss of cell growth control. Data presented here indicate that the first alternative is not fulfilled in the case of HPV6-T70. Although sequence differences do exist between HPV6-T70 and HPV6-W50, these changes do not affect the behaviour of the viral genome when standard assays are used to analyse enhancer activity and transforming potential. The hypothesis that sequence variation within the HPV-6 URR might be related to oncogenic potential arose from the observation that sequence duplications were present in the URRs of HPV-6 genomes isolated from an invasive verrucous carcinoma, HPV-6vc (Rando et al., 1986a) , a Buschke-L6wenstein tumour, HPV-6d (Boshart & zur Hausen, 1986) , and a non-keratinizing squamous cell carcinoma of the vulva, HPV6-T70 (Kasher & Roman, 1988 a) . However, sequence duplications are neither consistently detected in carcinomas nor consistently absent in benign lesions. Five HPV-6s from Buschke-L6wenstein tumours did not contain duplications (Boshart & zur Hausen, 1986) , whereas, HPV-6ma cloned from a benign condyloma of the mamilla did contain a duplication (Kulke et al., 1989) , as did HPV-6g cloned from a benign condyloma of the genital tract (Wu & Mounts, 1988) .
To determine the effect of alterations in the 5' end of the URR on enhancer function, we compared the enhancer activity of HPV6-T70 to that of HPV6-W50. Our results indicate that the sequence differences between HPV6-T70 and HPV6-W50 at nt 7323 and nt 7350 did not result in differences in enhancer activity. Previous comparisons of enhancer activity have been made between the genome carrying the duplication, HPV-6vc (Rando et al., 1986b) or HPV-6ma (Kulke et al., 1989) , and the prototype HPV-6b genome which has been found to have a deletion of 120 bp within the URR (Boshart & zur Hausen, 1986) ; or between two HPV-6s isolated from benign lesions (Wu & Mounts, 1988) . The insertions of 74 bp at nt 7348, 15 bp at nt 7418 and 19 bp at nt 7720 in the URR of HPV-6vc were shown to have greater enhancer activity than the same region of HPV6b when comparing the entire URRs (Rando et al., 1986b) . The 3' half of the URR of HPV-6vc, which contains only the 19 bp insertion, was also shown to have greater enhancer activity than the same region of HPV6b (Rando et al., 1986b) . Duplications ofnt 7681 to 7896 in the URR of HPV-6ma (Kulke et al., 1989) and the 136 bp tandem repeat at nt 7846 in the URR of HPV-6g (Wu & Mounts, 1988) have been shown to increase the enhancer activity of the URRs. These results may be explained by the locations of the insertions. Duplications in the 3' half of the URR may result in an increase in the number of trans-acting factors that are able to bind to the URR whereas duplications in the 5' region may not lead to such an increase. This is supported by the presence of more putative nuclear factor binding motifs in the 3' half of the URR (Fig. 4) . However, other cis elements may exist in the 5' region which have not yet been identified.
The insertions and deletions in HPV6-W50 and HPV6-T70 were all located in the purine-thymidine-rich region which is immediately upstream of the late polyadenylation signal. Differences in the length of the alternating purine-thymidine-rich sequence and putative length and strength of Z DNA did not alter enhancer activity. Alterations upstream of the polyadenylation signal may influence HPV-6 mRNA stability (Kennedy et al., 1990) rather than enhancer activity.
HPV6-W50 and HPV6-T70 URR plasmids transfected into HeLa cells exhibited similar levels of enhancer activity above the baseline of pSVEcat whereas little or no enhancer activity was seen in Veto cells; similar results are seen with an HPV-16 enhancer . The ability of the HPV-6 enhancers to function in HeLa cells but not in Veto cells may be due to the origin of the cells, i.e. epithelial (HeLa) or fibroblast-like (Vero), or may be due to the presence of HPV gene products in the HeLa cells. Since the HPV-16 URR is able to act as an enhancer in uninfected keratinocytes , we presume that the greater enhancer activity of the HPV-6 URR observed in HeLa cells is due to epithelium-specific factors.
Assays for enhancer activity and transforming potential showed that HPV6-T70 has no greater oncogenic potential than HPV6-W50, suggesting that the role of HPV6-T70 in the genesis of a carcinoma must be different from the role of HPV-16 and HPV-18. Since all HPVs have the ability to stimulate senescing cells to proliferate (Schlegel et al., 1988) , perhaps the role of HPV-6 in the genesis of a carcinoma is to provide a mitogenic stimulus. Thus, we would propose that all HPV-6s have the ability to stimulate cell proliferation; such stimulated cells may accumulate mutations in growth control genes such that, on rare occasions, a malignancy arises. This hypothesis suggests that the HPV-6 genome would not necessarily be maintained in a carcinoma. This is consistent with the observation that C 127 mouse cells morphologically transformed by HPV6b do not retain the HPV-6 genome (Morgan et al., 1990) . Either the infrequent accumulation of appropriate mutations in the cellular genome or the lack of required maintenance of the HPV-6 genome may account for the rare association of HPV-6 in carcinomas. This hypothesis also suggests that there need not be an alteration in the gene responsible for mitogenesis between the HPV-6 genome isolated from a benign and a malignant lesion. Recently, Chen & Mounts (1990) reported that the E5a ORF of HPV-6c, isolated from a benign lesion, transforms permanent mouse cell lines and suggested that it does so by stimulating cellular proliferation. Consistent with the hypothesis that all HPV-6s have the same mitogenic potential, the E5a ORF sequences are identical between HPV6-W50 and HPV6-T70 (data not shown).
